共 284 条
[1]
Ardizzoni A(2007)Cisplatin- versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis J Natl Cancer Inst 99 847-857
[2]
Boni L(2007)Excision repair cross-complementation group 1 predicts progression-free and overall survival in non-small cell lung cancer patients treated with platinum-based chemotherapy Cancer Sci 98 1336-1343
[3]
Tiseo M(2012)Prognostic and predictive role of the VeriStrat plasma test in patients with advanced non-small-cell lung cancer treated with erlotinib or placebo in the NCIC Clinical Trials Group BR.21 trial J Thorac Oncol 7 1653-1660
[4]
Fossella FV(2010)VeriStrat classifier for survival and time to progression in non-small cell lung cancer (NSCLC) patients treated with erlotinib and bevacizumab Lung Cancer 69 337-340
[5]
Schiller JH(2010)Detection of tumor epidermal growth factor receptor pathway dependence by serum mass spectrometry in cancer patients Cancer Epidemiol Biomarkers Prev 19 358-365
[6]
Paesmans M(2015)Outcomes of prognostic disclosure: associations with prognostic understanding, distress, and relationship with physician among patients with advanced cancer J Clin Oncol 33 3809-3816
[7]
Radosavljevic D(2013)VeriStrat(R) has a prognostic value for patients with advanced non-small cell lung cancer treated with erlotinib and bevacizumab in the first line: pooled analysis of SAKK19/05 and NTR528 Lung Cancer 79 59-64
[8]
Paccagnella A(2014)Predictive value of a proteomic signature in patients with non-small-cell lung cancer treated with second-line erlotinib or chemotherapy (PROSE): a biomarker-stratified, randomised phase 3 trial Lancet Oncol 15 713-721
[9]
Zatloukal P(2014)Serum mass-spectrometry test in first line advanced NSCLC patients treated with standard chemotherapy regimens Ann Oncol 25 iv426-iv470
[10]
Mazzanti P(2012)VeriStrat((R)) has prognostic value in advanced stage NSCLC patients treated with erlotinib and sorafenib Br J Cancer 107 1820-1825